Stock Events

Stock Events

ORIC Pharmaceuticals 

€11.14
36
-€0.20-1.72% Friday 06:03

Statistics

Day High
11.14
Day Low
11.14
52W High
12.6
52W Low
6.6
Volume
0
Avg. Volume
0
Mkt Cap
1.15B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9NovExpected
Q1 2026
Q2 2026
Next
-0.33
-0.31
-0.29
-0.27
Expected EPS
-0.32842684786
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-112.35MNet Income

Analyst Ratings

15.18Average Price Target
The highest estimate is 20.49.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4TZ.MU. It's not an investment recommendation.
Apple
9
AAPL
Microsoft
8
MSFT
NVIDIA
8
NVDA
AMD
8
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap162.16B
Pfizer is a global pharmaceutical company that competes with ORIC in the oncology sector, particularly in developing treatments for cancer.
Merck
MRK
Mkt Cap370.89B
Merck is a leading pharmaceutical company that competes directly with ORIC Pharmaceuticals in the cancer treatment space, with a strong focus on innovative oncology drugs.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol Myers Squibb is a major competitor in the oncology market, offering a range of cancer treatments that compete with ORIC's product pipeline.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is a global biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines in oncology, directly competing with ORIC.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences is known for its strong portfolio in oncology and inflammatory diseases, making it a direct competitor to ORIC Pharmaceuticals in cancer treatment research.
AMGEN
AMGN
Mkt Cap236.38B
Amgen is a biotechnology company with a focus on oncology and cardiovascular diseases, competing with ORIC in developing innovative cancer therapies.
Novartis
NVS
Mkt Cap304.1B
Novartis is a global healthcare company that competes with ORIC Pharmaceuticals in the oncology sector, with a wide range of cancer treatments.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a leading pharmaceutical and diagnostics company, competing with ORIC in the field of oncology through its extensive research and development in cancer treatments.
Lilly(Eli) &
LLY
Mkt Cap1.02T
Eli Lilly and Company is a competitor in the oncology market, with a focus on developing innovative cancer treatments that compete with ORIC's offerings.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.22B
Regeneron Pharmaceuticals is known for its research in oncology and other areas, making it a competitor to ORIC Pharmaceuticals in developing cancer therapies.

About

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Show more...
CEO
Jacob Chacko
Employees
111
Country
United States
ISIN
US68622P1093
WKN
000A2P208

Listings

MU
DE
4TZ.MU
STU
DE
4TZ.STU
F
DE
4TZ.F
XNAS
US
ORIC

0 Comments

Share your thoughts

FAQ

What is ORIC Pharmaceuticals stock price today?▼
The current price of 4TZ.MU is €11.14 EUR — it has decreased by -1.72% in the past 24 hours. Watch ORIC Pharmaceuticals stock price performance more closely on the chart.
What is ORIC Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange ORIC Pharmaceuticals stocks are traded under the ticker 4TZ.MU.
Is ORIC Pharmaceuticals stock price growing?▼
4TZ.MU stock has fallen by -4.13% compared to the previous week, the month change is a -0.54% fall, over the last year ORIC Pharmaceuticals has showed a +22.36% increase.
What is ORIC Pharmaceuticals market cap?▼
Today ORIC Pharmaceuticals has the market capitalization of 1.15B
When is the next ORIC Pharmaceuticals earnings date?▼
ORIC Pharmaceuticals is going to release the next earnings report on November 09, 2026.
What were ORIC Pharmaceuticals earnings last quarter?▼
4TZ.MU earnings for the last quarter are -0.33 EUR per share, whereas the estimation was -0.31 EUR resulting in a -5.75% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is ORIC Pharmaceuticals revenue for the last year?▼
ORIC Pharmaceuticals revenue for the last year amounts to 0 EUR.
What is ORIC Pharmaceuticals net income for the last year?▼
4TZ.MU net income for the last year is -112.35M EUR.
How many employees does ORIC Pharmaceuticals have?▼
As of September 07, 2026, the company has 111 employees.
In which sector is ORIC Pharmaceuticals located?▼
ORIC Pharmaceuticals operates in the Health & Wellness sector.
When did ORIC Pharmaceuticals complete a stock split?▼
ORIC Pharmaceuticals has not had any recent stock splits.
Where is ORIC Pharmaceuticals headquartered?▼
ORIC Pharmaceuticals is headquartered in SOUTH SAN FRANCISCO, United States.